Cargando…

Nonclinical Safety Assessment of a Long-Acting Recombinant PEGylated Factor Eight (BAY 94-9027) With a 60 kDa PEG

BAY 94-9027 (Jivi) is a site-specifically PEGylated human B-domain-deleted (BDD) recombinant factor VIII (FVIII), with a 60 kDa branched PEG molecule attached. The nonclinical safety of BAY 94-9027 was evaluated in a toxicology program that included 2 weeks intravenous (IV) toxicity studies in rats...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ivens, Inge A., Banczyk, David, Gutberlet, Katrin, Jackman, Shawna, Vauléon, Stéphanie, Frisk, Anna-Lena
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2019
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6696742/ https://www.ncbi.nlm.nih.gov/pubmed/31132933 http://dx.doi.org/10.1177/0192623319852300

Ejemplares similares

PROTECT VIII Kids: BAY 94‐9027 (PEGylated Recombinant Factor VIII) safety and efficacy in previously treated children with severe haemophilia A
por: Santagostino, Elena, et al.
Publicado: (2020)

Target joint resolution in patients with haemophilia A receiving long‐term prophylaxis with BAY 94‐9027
por: Reding, Mark T., et al.
Publicado: (2020)

Phase I study of BAY 94-9027, a PEGylated B-domain-deleted recombinant factor VIII with an extended half-life, in subjects with hemophilia A
por: Coyle, T E, et al.
Publicado: (2014)

Comparing Physician and Patient Perspectives on Prophylactic Treatment with BAY 94-9027 for Severe Haemophilia A: A Post Hoc Analysis
por: Lalezari, Shadan, et al.
Publicado: (2020)

Decreased Bleeding Rates in Patients with Hemophilia A Switching from Standard-Half-Life FVIII to BAY 94-9027 Prophylaxis
por: Mancuso, Maria Elisa, et al.
Publicado: (2021)

Exploring the Impact of Infusion Frequency in Hemophilia A: Exit Interviews with Patients Participating in BAY 94-9027 Extension Studies (PROTECT VIII)
por: Wells, Jane R., et al.
Publicado: (2019)

BAY 94‐9027 prophylaxis is efficacious and well tolerated for up to >5 years with extended dosing intervals: PROTECT VIII extension interim results
por: Lalezari, Shadan, et al.
Publicado: (2019)

Recombinant FVIIIFc Versus BAY 94-9027 for Treatment of Patients with Haemophilia A: Comparative Efficacy Using a Matching Adjusted Indirect Comparison
por: Hakimi, Zalmai, et al.
Publicado: (2020)

PROTECT VIII kids extension study: Long‐term safety and efficacy of BAY 94‐9027 (damoctocog alfa pegol) in children with severe haemophilia A
por: Mancuso, Maria Elisa, et al.
Publicado: (2021)

Confirmed long‐term safety and efficacy of prophylactic treatment with BAY 94–9027 in severe haemophilia A: final results of the PROTECT VIII extension study
por: Reding, Mark T., et al.
Publicado: (2021)

Favorable Pharmacokinetic Characteristics of Extended-Half-Life Recombinant Factor VIII BAY 94-9027 Enable Robust Individual Profiling Using a Population Pharmacokinetic Approach
por: Solms, Alexander, et al.
Publicado: (2019)

Matching-adjusted indirect comparisons of annualized bleeding rate and utilization of BAY 94-9027 versus three recombinant factor VIII agents for prophylaxis in patients with severe hemophilia A
por: Batt, Katharine, et al.
Publicado: (2019)

Pegylated interferon alpha-2a (40 kDa) in the treatment of chronic hepatitis B
por: Lai, Lawrence, et al.
Publicado: (2006)

Addition of 20-kDa PEG to Insulin Lispro Alters Absorption and Decreases Clearance in Animals
por: Knadler, Mary Pat, et al.
Publicado: (2016)

Cloning and promoter analysis of palladin 90-kDa, 140-kDa, and 200-kDa isoforms involved in skeletal muscle cell maturation
por: Ouali, Boimpoundi Eunice Flavie, et al.
Publicado: (2020)

Data on physicochemical properties of LPEI 25 kDa, PEI“Max” 40 kDa and PEIpro™
por: Delafosse, Laurence, et al.
Publicado: (2016)

In Vitro Inhibition of Angiogenesis by Antibodies Directed against the 37kDa/67kDa Laminin Receptor
por: Khusal, Raksha, et al.
Publicado: (2013)

Expression of the 60 kDa and 71 kDa heat shock proteins and presence of antibodies against the 71 kDa heat shock protein in pediatric patients with immune thrombocytopenic purpura
por: Xiao, Chengfeng, et al.
Publicado: (2004)

The 37kDa/67kDa Laminin Receptor acts as a receptor for Aβ(42) internalization
por: Da Costa Dias, Bianca, et al.
Publicado: (2014)

Knock-Down of the 37kDa/67kDa Laminin Receptor LRP/LR Impedes Telomerase Activity
por: Naidoo, Kerrilyn, et al.
Publicado: (2015)

Enhanced gene transfection efficiency by low-dose 25 kDa polyethylenimine by the assistance of 1.8 kDa polyethylenimine
por: Zhang, Hui, et al.
Publicado: (2018)

Proteomic analysis of ceftazidime and meropenem-exposed Pseudomonas aeruginosa ATCC 9027
por: Ngo, Hong Loan, et al.
Publicado: (2023)

The 18 kDa Translocator Protein, Microglia and Neuroinflammation
por: Liu, Guo‐Jun, et al.
Publicado: (2014)

Monodisperse 130 kDa and 260 kDa Recombinant Human Hemoglobin Polymers as Scaffolds for Protein Engineering of Hemoglobin-Based Oxygen Carriers
por: Marquardt, David A., et al.
Publicado: (2012)

Evaluation of the Prognostic Value of CD56 (140 kDa Isoform) Expression in Breast Cancer Tissues: an Eight-Year Retrospective Study
por: Niknam, Kianoush, et al.
Publicado: (2022)

MALDI-TOF High Mass Calibration up to 200 kDa Using Human Recombinant 16 kDa Protein Histidine Phosphatase Aggregates
por: Ludwig, Katrin, et al.
Publicado: (2011)

Antimicrobial Properties of an Immunomodulator - 15 kDa Human Granulysin
por: Wei, Hung-Mu, et al.
Publicado: (2016)

Structural Analysis of the 42 kDa Parvulin of Trypanosoma brucei
por: Rehic, Edisa, et al.
Publicado: (2019)

The Role of Heat Shock Protein 70 kDa in Asthma
por: Shevchenko, Marina, et al.
Publicado: (2021)

High Resolution Imaging Study of Interactions between the 37 kDa/67 kDa Laminin Receptor and APP, Beta-Secretase and Gamma-Secretase in Alzheimer's Disease
por: Jovanovic, Katarina, et al.
Publicado: (2014)

Identification of the Interactors of Human Nibrin (NBN) and of Its 26 kDa and 70 kDa Fragments Arising from the NBN 657del5 Founder Mutation
por: Cilli, Domenica, et al.
Publicado: (2014)

Immunoblot studies in the differential diagnosis of porcine brucellosis: an immunodominant 62 kDa protein is related to the mycobacterial 65 kDa heat shock protein (HSP-65)
por: Spencer, S.A., et al.
Publicado: (1994)

Physical mapping of human cytomegalovirus genes: Identification of DNA sequences coding for a virion phosphoprotein of 71 kDa and a viral 65-kDa polypeptide
por: Nowak, Barbara, et al.
Publicado: (1984)

SUN-LB62 Differential Regulation of 22 kDa and 20 kDa Growth Hormone Isoforms in Response to Acute Glucose Load and Moderate Intensity Exercise
por: Haenelt, Michael, et al.
Publicado: (2020)

Activity of the Bacillus anthracis 20 kDa protective antigen component
por: Hammamieh, Rasha, et al.
Publicado: (2008)

Immunoreactivity of the Mycobacterium avium subsp. paratuberculosis 19-kDa lipoprotein
por: Huntley, Jason FJ, et al.
Publicado: (2005)

Interactions of the 67 kDa laminin receptor and its precursor with laminin
por: Fatehullah, Aliya, et al.
Publicado: (2009)

Is the 32-kDa fragment the functional enamelin unit in all species?
por: Brookes, Steven J, et al.
Publicado: (2011)

Single-Photon Ionization of Organic Molecules Beyond 10 kDa
por: Schmid, Philipp, et al.
Publicado: (2013)

Evidence for a 12 kDa “Carrier Protein” for Natriuretic Hormone
por: Gonick, Harvey C.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_kpa1dnsd2igg0oov17b3rtqgse